Covid-19 Vaccine
Bharat Biotech announces completion of phase 3 clinical trials of Covid-19 vaccine
New Delhi/UNI: Bharat Biotech on Thursday announced that it has enrolled 25,800 volunteers for phase 3 clinical trials of its indigenously manufactured Covid-19 vaccine, 'Covaxin'.
''Announcing successful completion of volunteer enrollment for Phase-3 Clinical trials of COVAXIN,'' the Hyderabad-based company posted on it's official Twitter handle.
Announcing successful completion of volunteer enrolment for Phase-3 Clinical trials of COVAXINᵀᴹ.#BharatBiotech #COVAXIN #clinicaltrials #Covid19 #CovidVaccine #phase3 https://t.co/lIdXVpstDK
— BharatBiotech (@BharatBiotech) January 7, 2021
Joint Managing Director of Bharat Biotech International Limited Suchitra Ella said, ''COVAXIN successfully completes Phase 3 clinical trials enrollment of 25,800 volunteers.
''We sincerely express our gratitude to clinical trial sites, Principle Investigators & healthcare workers for their relentless support and trust in our Public-Private Partnership vaccine discovery."
''My deep appreciation to all the volunteers for reposing trust and expressing Pro Vaccine Public Health Volunteerism in the Phase-3 Clinical Trials of India's first fully indigenous COVID-19 Vaccine,'' she said.
The Drugs Controller General of India (DCGI) on January 3 approved the emergency use of Bharat Biotech's indigenously manufactured Coronavirus vaccine 'Covaxin' and 'Covishield,' manufactured by the Serum Institute of India, Pune.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
